GOLD DIGITAL INNOVATION PARTNER

About Argenta™

Founded in 2006 in New Zealand, Argenta’s talented and committed employees work on a daily basis to deliver excellence in animal health to customers around the world. With research and GMP manufacturing operations in New Zealand, the United States and the United Kingdom, Argenta holds a unique position as the only combined global contract research organization (CRO) and contract manufacturing organization (CMO) dedicated to animal health. 

Argenta operates from Molecule to Market in partnership with customers of all sizes from all corners of the world, supporting their research & development, clinical research, regulatory, scale up and manufacturing needs along their veterinary product development journey.

The day-to-day ethos that drives Argenta forward is a mission focused on global partnerships, a Molecule to Market approach, and innovation. At the core of the business and the organisation is collaboration —among the global employee base and with their customers. Working together, Argenta continually challenges the status quo to continuing to innovate to develop the best animal health technologies and products possible.

From animal scientists to veterinarians to engineers and other industry experts, Argenta’s 450+ strong global team is a passionate and diverse group united in their commitment to healthy animals. The company operates from Research & Development locations in New Zealand and the US and (EMA and FDA) GMP approved Manufacturing sites in New Zealand, the United Kingdom (Scotland) and the United States (Fort Dodge, Iowa).

Argenta proudly partners with a vast range of global clients —from small and medium-sized enterprises to the largest industry players. The R&D capabilities and manufacturing facilities scale to service the requirements of the largest multinationals, while, at the other end of the spectrum, Argenta works with startups and small companies by offering capabilities and solutions that help bring their ideas to fruition.

For more information, please visit www.argentaglobal.com.

MEET OUR TEAM

BOOK A MEETING
Stephen Bienhoff Stephen Bienhoff
Argenta
Chief Scientific Officer
Ben Isaacs Ben Isaacs
Argenta
Head of Pharmaceutical Sciences USA
Peter McCarthy Peter McCarthy
Argenta
Chief Operating Officer North America
Edward McGruder Edward McGruder
Argenta
Global Head of Research, Development and Innovation
Ian Williams Ian Williams
Argenta Limited
Business Development and Global Customer Insights Manager
Bill Zollers Bill Zollers
Argenta
Head of Regulatory Affairs

VIEW OUR SESSION

Name
Developing Medical Breakthroughs for Both Humans and Animals: Regulation Need-to-Knows
Date & Time
Tuesday, June 15, 2021, 12:00 PM - 12:30 PM
Speakers
Linda Rhodes - Independent Consultant
Bill Zollers - Argenta
Linda Rhodes Bill Zollers
Description

The road to an NADA compared to an NDA is shorter, and less costly, but still very challenging and difficult. There are many ways in which the regulatory path in animal health is less risky than in human health, not least because of the ability to do pilot studies in the client-owned animal population. In fact, almost no pivotal clinical studies fail for lack of effectiveness because pilot studies can be done prior to launching the pivotal study. This roundtable will address how to navigate the registration process in animal health, and share tricks of the trade that you need to know to get your product to market quickly.

Session Type
Panel
Virtual Session Link
View Session